Skip to main content
NCBI home page
PLOS One logoLink to PLOS One
. 2022 Mar 30;17(3):e0264157. doi: 10.1371/journal.pone.0264157

Patterns and prognosis of holding regimens for people living with HIV in Asian countries

Jung Ho Kim 1, Awachana Jiamsakul 2, Sasisopin Kiertiburanakul 3, Bui Vu Huy 4, Suwimon Khusuwan 5, Nagalingeswaran Kumarasamy 6, Oon Tek Ng 7, Penh Sun Ly 8, Man-Po Lee 9, Yu-Jiun Chan 10, Yasmin Mohamed Gani 11, Iskandar Azwa 12, Anchalee Avihingsanon 13,14, Tuti Parwati Merati 15, Sanjay Pujari 16, Romanee Chaiwarith 17, Fujie Zhang 18, Junko Tanuma 19, Cuong Duy Do 20, Rossana Ditangco 21, Evy Yunihastuti 22, Jeremy Ross 23, Jun Yong Choi 1,*; on behalf of IeDEA Asia-Pacific
Editor: Carlo Torti24
PMCID: PMC8967045  PMID: 35353840

Abstract

The use of holding regimens for people living with HIV (PLWH) without effective antiretroviral options can have effects on outcomes and future treatment options. We aimed to investigate the use of holding regimens for PLWH in Asian countries. Data from adults enrolled in routine HIV care in IeDEA Asia-Pacific cohorts were included. Individuals were considered to be on holding regimen if they had been on combination antiretroviral therapy for at least 6 months, had two confirmed viral loads (VL) ≥1000 copies/mL, and had remained on the same medications for at least 6 months. Survival time was analyzed using Fine and Gray’s competing risk regression. Factors associated with CD4 changes and VL <1000 copies/mL were analyzed using linear regression and logistic regression, respectively. A total of 425 PLWH (72.9% male; 45.2% high-income and 54.8% low-to-middle-income country) met criteria for being on a holding regimen. From high-income countries, 63.0% were on protease inhibitors (PIs); from low-to-middle-income countries, 58.4% were on non-nucleoside reverse transcriptase inhibitors (NNRTIs); overall, 4.5% were on integrase inhibitors. The combination of lamivudine, zidovudine, and efavirenz was the most commonly used single regimen (n = 46, 10.8%), followed by lamivudine, zidovudine, and nevirapine (n = 37, 8.7%). Forty-one PLWH (9.7%) died during follow-up (mortality rate 2.0 per 100 person-years). Age >50 years compared to age 31–40 years (sub-hazard ratio [SHR] 3.29, 95% CI 1.45–7.43, p = 0.004), and VL ≥1000 copies/ml compared to VL <1000 copies/mL (SHR, 2.14, 95% CI 1.08–4.25, p = 0.029) were associated with increased mortality, while higher CD4 counts were protective. In our Asia regional cohort, there was a diversity of holding regimens, and the patterns of PI vs. NNRTI use differed by country income levels. Considering the high mortality rate of PLWH with holding regimen, efforts to extend accessibility to additional antiretroviral options are needed in our region.

Introduction

Combination antiretroviral therapy (cART) suppresses HIV replication, prevents opportunistic infections, and allows people living with HIV (PLWH) to live longer [1]. Because of the broader range of cART available, virologic suppression is now generally attainable with good adherence, even in PLWH with previous treatment failure and drug resistance [2, 3]. However, in countries where access to second- or third-line cART is limited, managing those with repeated virologic failure is often challenging [4]. Furthermore, resistance to integrase strand transfer inhibitors (INSTIs) is beginning to create additional challenges for HIV management [5, 6].

For PLWH with no available effective treatment options, guidelines consider continuing treatment to avoid clinical deterioration [7, 8]. Previous studies have shown that continued treatment in PLWH with virological failure to all three antiretroviral-drug classes could reduce the risk of disease progression [9, 10]. However, maintaining treatment with viral replication is a major contributor to the emergence of resistant mutations that can compromise future treatment options [11, 12]. There are no universal criteria for treating PLWH who have experienced multiple treatment failures, because treatment options differ according to the available cART of the countries and likelihood of resistance. For example, patients who develop resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) could achieve viral suppression by changing to a protease inhibitor (PI)-based or an INSTI-based regimen [5, 13]. Still, in some cases, since access to the drugs was limited due to problems such as cost and availability, they should maintain their regimens [14].

When no fully suppressive cART options are available, providers may choose to maintain patients on “holding regimens” in anticipation of future treatments [7]. The use of holding regimens could have effects on the future immunologic and clinical outcomes of the PLWH. However, studies on the status, patterns and prognosis of holding regimens are limited in Asian countries. Therefore, we aimed to investigate the patterns and prognosis of holding regimens for Asian PLWH without effective drug options.

Materials and methods

Data sources

This study included data from the TREAT Asia HIV Observational Database (TAHOD) and TAHOD-Low Intensity TransfEr (TAHOD-LITE). TAHOD is a prospective observational cohort study involving 21 participating clinical sites in 12 countries in the Asia and Pacific region, which is a contributing cohort to the International Epidemiology Databases to Evaluate AIDS (IeDEA) global cohort consortium. TAHOD-LITE collects a simplified dataset from all PLWH who have received care at participating 10 sites in Cambodia, Hong Kong SAR, India, Indonesia, Singapore, South Korea, Taiwan, and Vietnam, contributing data from over 49,000 PLWH. A detailed description of the TAHOD and TAHOD-LITE databases and methods has been previously published [15–17]. Ethics approvals for the study were obtained from the coordinating center (TREAT Asia ethics/amfAR, Bangkok, Thailand), the data management and analysis center (University of New South Wales Human Research Ethics Committee, Sydney, Australia), and local institutional review boards for each participating site including the institutional review board of Yonsei University Health System Clinical Trial Center. Because of the pure observational nature of the study, written informed consent was waived for both TAHOD and TAHOD-LITE unless required by local institutional review board. All TAHOD and TAHOD-LITE data transfers are anonymized before submission to the Kirby Institute.

Study population

TAHOD subjects were included if they were enrolled up to the September 2018 data transfer, whilst TAHOD-LITE subjects were included from the 2017 data transfer. For TAHOD, enrolment was the date the patient was recruited into the cohort which can be after ART initiation. For TAHOD-LITE, enrolment was the date the patient was first seen at the site. The latest follow-up date for TAHOD-LITE was July 2017. We defined PLWH meeting all of the following criteria as taking holding regimens: 1) have initiated cART and been on it for at least 6 months; 2) had virologic failure defined as viral load (VL) ≥1000 copies/mL on two consecutive tests performed within 6 months while on the same regimen [18]; and 3) then remained on the same regimen for at least 6 months after the second VL test. The holding regimen itself can include mono/dual therapy. These definitions applied regardless of the number of drugs that make up the regimen or the category of regimen the subject was on (e.g., 1st, 2nd, or 3rd regimen). Subjects who switched after the first VL test and subjects who switched before 24 weeks after the second VL test were excluded because they did not meet the definition of holding regimen (Fig 1).

Fig 1. Schematic representation of definition of holding regimen.

Fig 1

Open in a new tab

* Regimen A refers to holding regimen.

Outcome definitions

The baseline time point of our study was defined as the time of the second VL ≥1000 copies/mL. The primary outcome was identifying which diverse regimens were used as holding regimens in our study population. The secondary outcome was to assess the prognosis of PLWH who had been on holding regimens. To evaluate their prognosis, we further investigated mortality, and changes in CD4 count and VL. Because all included individuals were alive at 6 months after their second VL test (per the definition of being on a holding regimen), survival time was left truncated at 6 months after the second VL test. PLWH were included in the CD4 and VL outcomes analyses if they had at least one CD4 count or VL test within 6 months prior to the baseline time point and at least one CD4 count or VL test at week 24 (+/-12 weeks window period) or at week 48 (+/-12 weeks window period) after baseline. PLWH without measurements at these two time points were not included in the analyses. Changes in CD4 measurements refer to the difference between the CD4 taken at 24 or 48 weeks, compared to the measurement taken at baseline. VL was classified into two groups based on 1000 copies/mL at 24 or 48 weeks. Countries were split into lower-middle income countries (LMICs), upper-middle income countries (UMICs), and high-income countries (HICs) based on World Bank categorizations [19].

Statistical analysis

Descriptive statistics were used to describe patterns of holding regimen use. Survival time from 6 months after the second VL test was analyzed using Fine and Gray competing risk regression, with loss to follow-up (LTFU) included as competing risk. LTFU was defined as those not seen in the previous 12 months. Survival was analysed using intention to treat methods. Survival time ended on the date of death, with censoring occurring on the date of transfer or last follow-up. Baseline age, sex, mode of HIV exposure, hepatitis B/C co-infection defined as ever having positive hepatitis B virus surface antigen or positive hepatitis C virus antibody, number of previous regimen changes (defined as a change of two drugs or drug class for any reason), prior mono/dual therapy, year of ART initiation, the holding ART regimen combination, and World Bank country income group were evaluated as time-fixed covariates. CD4 count, VL, and duration of ART (<5 years, 5–10 years, ≥10 years) were evaluated as time-updated covariates. Linear regression was used to analyze factors associated with CD4 changes at 24 weeks and at 48 weeks. Logistic regression was used to analyze factors associated with VL <1000 copies/mL at 24 weeks and at 48 weeks. All analyses were adjusted for World Bank country income group. Data management and statistical analyses were performed using SAS software version 9.4 (SAS Institute Inc., Cary, NC, USA) and Stata software version 14.2 (Stata Corp., College Station, TX, USA).

Results

Baseline characteristics

A total of 425 PLWH met the inclusion criteria for being on a holding regimen and were included in the analysis. The median year of enrolment into the cohort was 2007 (IQR 2004–2010). The median age at baseline was 39 years (interquartile range [IQR] 33 to 46), and 72.9% of subjects were male. Heterosexual contact was the primary route of HIV exposure (69.4%). Median baseline VL was 12,300 copies/mL (IQR 2826 to 59,700), and median baseline CD4 counts were 240 cells/μL (IQR 137 to 389). Majority of subjects were from HICs (45.2%), followed by LMICs (37.9%). There were 211 (49.7%) patients who had no previous ART regimen changes, i.e. currently failing first-line ART. Overall, the combination of nucleoside reverse transcriptase inhibitor (NRTI) + NNRTI and the combination of NRTI + PI were used almost equally as holding regimens (44.2% vs. 44.5%, respectively) (Table 1).

Table 1. Baseline characteristics of patients with holding regimens.

　 Total
(N = 425)
Follow-up years from baseline, Median (IQR) 3.1 (1.4–6.8)
Baseline age (years)
    Median (IQR) 39 (33–46)
    ≤30 69 (16.2)
    31–40 167 (39.3)
    41–50 118 (27.8)
    >50 71 (16.7)
Sex
    Male 310 (72.9)
    Female 115 (27.1)
HIV mode of exposure
    Heterosexual contact 295 (69.4)
    MSM 78 (18.4)
    Injecting drug use 17 (4.0)
    Other/Unknown 35 (8.2)
Baseline viral Load (copies/mL)
    Median (IQR) 12,300 (2836–59,700)
    <5000 157 (36.9)
    ≥5000 268 (63.1)
Baseline CD4 (cells/μL)
    Median (IQR) 240 (137–389)
    ≤200 169 (39.8)
    201–350 114 (26.8)
    351–500 61 (14.4)
    >500 62 (14.6)
    Not tested 19 (4.5)
ART duration at baseline (years)
    Median (IQR) 4.0 (1.8–6.9)
    <5 249 (58.6)
    to <10 142 (33.4)
    ≥10 34 (8.0)
Prior mono/dual therapy before ART initiation
    No 349 (82.1)
    Yes 76 (17.9)
Number of previous ART regimen changes
    None 211 (49.6)
    1 141 (33.2)
    ≥ 2 73 (17.2)
Holding ART regimen
    NRTI+NNRTI 188 (44.2)
    NRTI+PI 189 (44.5)
    Other combination 48 (11.3)
Hepatitis B co-infection
    Negative 321 (75.5)
    Positive 23 (5.4)
    Not tested 81 (19.1)
Hepatitis C co-infection
    Negative 270 (63.5)
    Positive 28 (6.6)
    Not tested 127 (29.9)
World Bank country income level
    Lower middle 161 (37.9)
    Upper middle 72 (16.9)
    High 192 (45.2)
Open in a new tab

Note: Baseline time point refers to date of second VL > = 1000 copies/mL

Values are n (% total) unless otherwise indicated. ART, antiretroviral therapy; IQR, interquartile range; MSM, Men who have sex with men; NNRTI, non-nucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor

Patterns of holding regimen

Overview

The combination of 3TC, zidovudine (AZT), and efavirenz (EFV) was the most commonly used single regimen (n = 46, 10.8%), followed by 3TC + AZT + nevirapine (NVP) (n = 37, 8.7%), 3TC + tenofovir disoproxil fumarate (TDF) + atazanavir/ritonavir (ATV/r) (n = 33, 7.8%), and 3TC + TDF + EFV (n = 29, 6.8%). Combinations other than NRTI + NNRTI and NRTI + PI accounted for 11.3% of the total, with 19 PLWH (4.5%) using INSTIs (none on dolutegravir [DTG]; S1 Table).

Classified by World Bank country-income level

In HICs, PI-based regimens were most commonly used (63.0%), of which a regimen consisted of 3TC + TDF + ATV/r was the most popular regimen (n = 18, 9.4%). In LMICs and UMICs, NNRTI-based regimens were mainly used (58.4%). The combination of 3TC + AZT + NVP was the most popular regimen in LMICs (n = 30, 18.6%), followed by 3TC + AZT + EFV (n = 27, 16.8%). In UMICs, 3TC + AZT + EFV was the most commonly used (n = 10, 13.9%), followed by didanosine + D4T + EFV (n = 8, 11.1%) (Table 2).

Table 2. Patterns of holding regimens by World Bank country-income level.
Country-income group ART Number of patients Percent
Lower-middle income countries 3TC+AZT+NVP 30 18.6
　 3TC+AZT+EFV 27 16.8
　 3TC+TDF+ATV/r 15 9.3
　 3TC+TDF+EFV 13 8.1
　 TDF+FTC+LPV/r 11 6.8
　 Other 65 40.4
　 Total 161 100
Upper-middle income countries 3TC+AZT+EFV 10 13.9
　 DDI+D4T+EFV 8 11.1
　 3TC+D4T+NVP 6 8.3
　 3TC+D4T+EFV 5 6.9
　 3TC+AZT+IDV 4 5.6
　 Other 39 54.2
　 Total 72 100
High income countries 3TC+TDF+ATV/r 18 9.4
　 3TC+TDF+EFV 14 7.3
　 3TC+TDF+LPV/r 13 6.8
　 3TC+AZT+LPV/r 11 5.7
　 Other 136 70.8
　 Total 192 100
Open in a new tab

Note: ART combinations comprising of less than 5% were grouped as Other. 3TC, lamivudine; ATV/r, atazanavir/ritonavir; AZT, zidovudine; D4T, stavudine; DDI, didanosine; EFV, efavirenz; FTC, emtricitabine; IDV, indinavir; LPV/r, lopinavir/ritonavir; NVP, nevirapine; TDF, tenofovir disoproxil fumarate

Classified by previous regimen changes

In cases where PLWH were left on failing first regimens, 3TC + AZT + EFV was the most commonly used (n = 38, 18.0%), followed by 3TC + AZT + NVP (n = 34, 16.1%). Among those who had previously changed their regimens (e.g., to a second or third combination), 3TC + TDF + ATV/r was the most commonly used regimen in both patients who changed once (n = 26, 18.4%) and who changed more than once before (n = 6, 8.2%; S2 Table).

Survival analysis

Of the 425 patients included in the survival analysis, there were 41 (9.7%) deaths (mortality rate 2.0 per 100 person-years), and 80 (18.8%) were LTFU. The median follow-up time from baseline was 3.1 years (IQR 1.4–6.8). Out of 41 deaths, 21 were AIDS-related, 14 were non-AIDS-related, and 6 were deaths by unknown causes. Univariate analysis showed that baseline age (p = 0.026), VL (p = 0.001), and CD4 count (p <0.001) were associated with mortality. In multivariate analysis, factors associated with increased mortality, whilst adjusting for country-income, were ages >50 years compared to ages 31 to 40 years (SHR 3.29, 95% CI 1.45 to 7.43, p = 0.004), and VL ≥1000 copies/ml compared to VL <1000 copies/mL (SHR, 2.14, 95% CI 1.08 to 4.25, p = 0.029). On the other hand, higher CD4 count had protective effects against mortality. The SHR for mortality of CD4 count 351–500 and CD4 >500 compared to CD4 count ≤200 cells/μL were 0.20 (95% CI 0.06 to 0.67, p = 0.009) and 0.25 (95% CI 0.08 to 0.80, p = 0.020), respectively (Table 3). Additional analyses were conducted where we accounted for changes from holding regimen (any changes to the holding ART or periods of no ART for >14 days). There were 271 patients who had changed out of their holding regimen however it was not associated with survival in the univariate analysis (SHR = 0.89, 95%CI 0.48–1.68, p = 0.719).

Table 3. Factors associated with mortality among patients who were on holding regimen.
Univariate Multivariate
　 No. patients Follow up (years) No. deaths Mortality rate (/100pys) SHR (95% CI) p-value SHR (95% CI) p-value
Total 425 2055 41 2.0
Baseline age (years) 0.026 0.024
    ≤30 69 351 6 1.7 1.20 (0.45, 3.20) 0.720 1.14 (0.42, 3.10) 0.797
    31–40 167 944 13 1.4 1 1
    41–50 118 483 12 2.5 1.81 (0.83, 3.92) 0.135 1.62 (0.74, 3.56) 0.232
    >50 71 275 10 3.6 3.03 (1.31, 7.04) 0.010 3.29 (1.45, 7.43) 0.004
Sex
    Male 310 1508 32 2.1 1
    Female 115 546 9 1.7 0.74 (0.35, 1.56) 0.427
HIV mode of exposure 0.697
    Heterosexual contact 295 1439 29 2.0 1
    MSM 78 384 7 1.8 1.01 (0.44, 2.32) 0.986
    Injecting drug use 17 77 3 3.9 1.83 (0.57, 5.86) 0.310
    Other/Unknown 35 154 2 1.3 0.69 (0.17, 2.76) 0.597
Viral Load (copies/mL)
    <1000 ~ 1358 14 1.0 1 1
    ≥1000 ~ 696 27 3.9 2.92 (1.57, 5.46) 0.001 2.14 (1.08, 4.25) 0.029
CD4 (cells/μL) <0.001 0.002
    ≤200 ~ 469 21 4.5 1 1
    201–350 ~ 483 11 2.3 0.59 (0.28, 1.23) 0.159 0.74 (0.35, 1.56) 0.426
    351–500 ~ 469 3 0.6 0.16 (0.05, 0.53) 0.003 0.20 (0.06, 0.67) 0.009
    >500 ~ 608 4 0.7 0.17 (0.06, 0.54) 0.002 0.25 (0.08, 0.80) 0.020
    Not tested ~ 25 2 7.8
ART duration at baseline (years) 0.297
    <5 249 1510 27 1.8 1
    5 to <10 142 465 12 2.6 1.63 (0.77, 3.43) 0.202
    ≥ 10 34 79 2 2.5 2.49 (0.52, 11.85) 0.251
Prior mono/dual therapy before ART initiation
    No 349 1341 33 2.5 1
    Yes 76 714 8 1.1 0.58 (0.26, 1.28) 0.174
Holding ART regimen 0.994
    NRTI + NNRTI 188 899 19 2.1 1
    NRTI + PI 189 897 17 1.9 0.99 (0.50, 1.95) 0.974
    Other combination 48 258 5 1.9 1.05 (0.37, 2.99) 0.931
Number of previous ART regimen changes 0.157
    None 211 1189.3 21 1.8 1
    1 141 600.0 11 1.8 1.20 (0.56, 2.58) 0.636
    ≥ 2 73 266.2 9 3.4 2.16 (0.98, 4.77) 0.057
Year of ART initiation 0.033
    ≤2002 122 1141.8 12 1.1 1 0.720
    2003–2005 58 271.4 9 3.3 3.12 (1.36, 7.18) 0.007
    2006–2009 150 487.3 14 2.9 1.95 (0.95, 4.02) 0.069
    2010–2015 95 155.1 6 3.9 2.37 (0.88, 6.37) 0.088
Hepatitis B co-infection
    Negative 321 1631 32 2.0 1
    Positive 23 107 3 2.8 1.61 (0.51, 5.12) 0.415
    Not tested 81 317 6 1.9
Hepatitis C co-infection
    Negative 270 1374 28 2.0 1
    Positive 28 140 5 3.6 1.50 (0.61, 3.70) 0.377
    Not tested 127 540 8 1.5
Country income level 0.836 0.996
    Lower middle 161 455 13 2.9 1
    Upper middle 72 572 9 1.6 0.80 (0.36, 1.78) 0.577 (0.45, 2.36) 0.934
    High 192 1028 19 1.9 0.98 (0.49, 1.95) 0.944 (0.49, 2.03) >0.999
Open in a new tab

~ CD4 and VL are time-updated variables. Global p-values are test for heterogeneity excluding missing values. P-values for age, CD4 and year of ART initiation are test for trend. P-values in bold represent significant covariates in the final model. Note: Baseline time point refers to date of second VL≥1000 copies/mL. ART, antiretroviral therapy; CI, confidence interval; NNRTI, non-nucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PYS, person-years; SHR, sub-hazard ratio

Subgroup analysis

Subgroup analysis was performed on PLWH with available follow-up CD4 cell count and VL results. Twenty-eight PLWH were included in the 24 week CD4 cell count analysis. On average, the CD4 count increased by 25.1 cells/μL at 24 weeks after baseline. Multivariate analysis showed that ages 41 to 50 years were associated with decrease in CD4 count compared to ages 31 to 40 years (Difference-133.3, 95% CI -232.4 to -34.2, p = 0.011), while PI-based holding regimen was associated with increase in CD4 count compared to NNRTI-based holding regimen (Difference 124.7, 95% CI 30.3 to 219.2, p = 0.012) (Table 4). For VL follow-up analysis, a total of 33 PLWH had a VL measurement available at 24 weeks, of whom 11 were undetectable (33%). The proportion with undetectable VL according to the number of previous ART regimen changes were: no previous ART regimen changes—5/14 (36%); 1 previous ART changes—5/12 (42%); and ≥2 previous ART changes—1/7 (14%). Country-income level was the only factor associated with having undetectable VL at 24 weeks where those living in HICs were more likely to achieve undetectable VL (OR = 17.50, 95% CI 1.70 to 180.02, p = 0.016). The changing patterns of mean CD4 cell count at 24 and 48 weeks after baseline and proportion of PLWH with VL<1000 copies/mL at 24 and 48 weeks after baseline can be seen in Figs 2 and 3. In Fig 2, there were 28 patients included at 24 weeks and 38 patients at 48 weeks. In Fig 3, of the total 66 patients, 33 patients each were included at 24 and 48 week time points. At 24 weeks, there were 11 patients with VL <1000 copies/mL, of those 7 patients had VL<200 copies/mL and 6 patients had VL<50 copies/mL. At 48 weeks, there were 15 patients with VL <1000 copies/mL, of those 11 patients had VL <200 copies/mL and 8 patients had VL <50 copies/mL.

Table 4. Factors associated with CD4 cell count changes at 24 weeks from baseline in patients with holding regimens.

Univariate Multivariate
　 No. patients Mean CD4 change (cells/μL) Diff (95% CI) p-value Diff (95% CI) p-value
Total 28 25.1
Baseline age (years) 0.011 0.047
    ≤30 6 6.3 -59.9 (-174.5, 54.7) 0.291 -65.8 (-181.8, 50.3) 0.251
    31–40 9 66.2 Ref Ref
    41–50 9 -61.8 -128.0 (-230.5, -25.5) 0.017 -133.3 (-232.4, -34.2) 0.011
    >50 4 156.3 90.0 (-40.6, 220.7) 0.168 31.3 (-108.4, 170.9) 0.646
Sex
    Male 20 27.3 Ref
    Female 8 19.6 -7.7 (-117.0, 101.6) 0.886
HIV mode of exposure 0.373
    Heterosexual contact 18 9.5 Ref
    MSM 5 106.4 96.9 (-32.7, 226.5) 0.136
    Injecting drug use 3 36.0 26.5 (-133.3, 186.3) 0.735
    Other/Unknown 2 -54.0 -63.5 (-254.5, 127.5) 0.499
Baseline viral Load (copies/mL)
    <5000 8 6.4 Ref
    ≥5000 20 32.6 26.2 (-82.6, 135.0) 0.625
Baseline CD4 (cells/μL) 0.424
    ≤200 7 68.4 Ref
    201–350 11 25.5 -43.0 (-167.7, 81.8) 0.484
    351–500 7 -36.9 -105.3 (-243.2, 32.6) 0.128
    >500 3 67.3 -1.1 (-179.1, 176.9) 0.990
ART duration at baseline (years) 0.959
    <5 17 20.5 Ref
    5 to <10 7 27.3 6.8 (-112.9, 126.5) 0.908
    ≥ 10 4 41.0 20.5 (-127.6, 168.7) 0.778
Holding ART regimen 0.023 0.039
    NRTI + NNRTI 12 -22.8 Ref Ref
    NRTI + PI 9 115.4 138.3 (36.9, 239.6) 0.009 124.7 (30.3, 219.2) 0.012
    Other combination 7 -8.9 14.0 (-95.3, 123.3) 0.794 58.5 (-41.7, 158.6) 0.238
Number of previous ART regimen changes 0.341
    None 14 -9.9 Ref
    1 6 66.3 76.2 (-48.6, 201.0) 0.220
    ≥ 2 8 55.4 65.2 (-48.1, 178.6) 0.247
Year of ART initiation
    <2010 14 35.6 Ref
    ≥2010 14 14.6 -21.1 (-119.5, 77.3) 0.664
Hepatitis C co-infection
    Negative 11 7.3 Ref
    Positive 3 36.0 28.7 (-144.0, 201.5) 0.735
    Not tested 14 36.8
Country income level 0.155 0.609
    Lower middle 17 -2.9 Ref Ref
    Upper middle 2 168.0 170.9 (-14.3, 356.2) 0.069 69.2 (-102.3, 240.7) 0.410
    High 9 46.3 49.3 (-52.9, 151.4) 0.330 -8.9 (-109.7, 91.9) 0.856
Open in a new tab

P-values in bold represent significant covariates in the final model. Global p-values are test for heterogeneity excluding missing values. Note: Baseline time point refers to date of second VL≥1000 copies/mL. ART, antiretroviral therapy; CI, confidence interval; NNRTI, non-nucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor

Fig 2. Changes in the mean CD4 cell counts in patients with holding regimens.

Fig 2

Open in a new tab

Fig 3. Proportion of undetectable viral load in patient with holding regimens. VL: Viral load.

Fig 3

Open in a new tab

Discussion

HIV management has been shifting from prevention of opportunistic infections to managing HIV as a chronic disease with a focus on addressing non-communicable diseases and improving quality of life. However, this paradigm shift is only possible when PLWH are on virally suppressive cART regimens, which may not be achievable when there is drug resistance or limited access to the antiretroviral drug options. This has led to the reliance on holding regimens in anticipation of future treatments. We found that 3TC + AZT + EFV was the most commonly used holding regimen in our Asia regional cohort, followed by 3TC + AZT + NVP.

The diverse patterns of holding regimen in our region is likely be due to differential cART access, national treatment guidelines, and health insurance options for PLWH in each country. For example, in Thailand, one of the UMICs, the 2014 national guidelines recommended EFV, one of the NNRTIs, as the first-line combination, and another NNRTI, NVP was recommended as an alternative drug. PIs were only recommended in second-line combinations and INSTIs in multi-class failure [20]. One reason for this is because many resource-limited countries, such as Thailand, could not financially afford the subsequent regimens [14]. However, in South Korea, one of the HICs, NVP was excluded from their 2013 national guidelines, and the INSTI raltegravir was recommended as a first-line drug [21]. Dutta et al. reported that there was still no ideal matching between actual clinical needs and available antiretroviral drugs in the Asia-Pacific [22]. In our retrospective study, only 4.5% of PLWH with holding regimens were on INSTIs, reflecting limited access to antiretrovirals like DTG. However, recent price reductions in DTG and introduction of generic formulations is likely to change future treatment options [23]. Efforts to use DTG and other new antiretroviral drugs in middle income countries have been continuing and are expected to have potential to overcome clinical unmet needs [24–26]. Future studies in this regard is warranted to monitor trend change of holding regimens.

The mortality rate of PLWH with holding regimens was more than twice that of other PLWH in our cohort reported in previous study [27]. This was consistent with the results of previous studies that the prognosis of a remaining regimen or a delay in switching regimens was poor in patients with virologic failure [28, 29]. The reasons for no switch or a delayed switch could be multifactorial, such as prolonged time-period before confirmation of virologic failure or doubts about adequate patient adherence [28, 29]. Still, there are cases of virologic failure even though a second-line or third-line regimen was already used with no other antiretroviral options available, as in this study. In particular, AIDS-related deaths were more common than non-AIDS-related deaths in this study, which differed from the previous results regarding the cause of death in TAHOD patients, where non-AIDS-related mortality rate was higher than AIDS-related mortality rate [27]. This fact demonstrates the need to extend accessibility to additional antiretroviral options in our region to improve their survival. Regarding factors associated with mortality, it was consistent with what is previously known that old age, high VL, and low CD4 cell counts increased mortality and supported our results that AIDS-related deaths were more common than non-AIDS-related deaths [30, 31]. There was no difference in mortality according to the holding regimens. On the other hand, PI-based holding regimen increased CD4 cell counts more than NNRTI-based holding regimens at 24 weeks after baseline. Old age was associated with poor prognosis in that not only increased mortality, but also decreased CD4 cell counts at 24 weeks after baseline. Meanwhile, the differences in mortality and CD4 cell counts changes according to World Bank country income levels were not identified. HICs was the only variable associated with undetectable VL at 24 weeks after baseline.

This study had several limitations. First, measurement of VL in TAHOD and TAHOD-LITE sites normally performed once a year, so we have small sample sizes due to our definition of 2 consecutive VL failure within 6 months. Second, TAHOD has patients who have been enrolled for a long time, so the data may reflect holding regimen in previous years. Since the median year of enrolment into the cohort was 2007 (IQR 2004–2010) and as INSTIs have not been widely available across all TAHOD sites, we could not identify the changes in patterns of holding regimen after INSTIs became widely available. Follow-up studies are warranted in this regard. Third, TAHOD-LITE does not collect ART adherence and therefore, we were not able to assess the impact of adherence counselling on our outcomes. Holding regimens are also sometimes used when adherence to ART is judged to be sub-optimal, especially for children who have suspected or proven poor adherence [32, 33]. However, TAHOD is for adult PLWH, and as TAHOD participating sites are generally urban referral centres, and each site recruits patients who are judged to have a reasonably good prospect of long-term follow-up, it is unlikely that holding regimens were used to ensure adherence in this study [34]. Fourth, data on resistance mutations in our study population were not available. In previous studies on resistance mutations in TAHOD patients, transmitted drug resistance was identified in 4.1%; 60% of which had NRTI, 43% NNRTI, and 18% PI-associated mutations [35]. The most common NRTI-associated mutation was M184V, the common NNRTI-associated mutation was K103N or Y181C, and the common PI-associated mutation was M46L [35, 36]. The results could be referred to in our study.

Conclusions

The patterns of holding regimens used in our cohort differed by country income levels. In LMICs and UMICs, NNRTI-based regimens including 3TC + AZT + EFV were most commonly used, but PI-based regimens were commonly used in HICs. The mortality of PLWH with holding regimens was higher than that of other PLWH in our cohort; old age, high VL, and low CD4 cell counts were associated with high mortality. Considering the high mortality rate of PLWH with holding regimen, efforts to extend accessibility to additional antiretroviral options are needed in our region.

Supporting information

S1 Table. Detailed patterns of holding regimens.

3TC, lamivudine; ABC, abacavir; ATV, atazanavir; AZT, zidovudine; COB, cobicistat; D4T, stavudine; DDC, zalcitabine; DDI, didanosine; DRV, darunavir; EFV, efavirenz; ETV, etravirine; EVG, elvitegravir; FAP, fosamprenavir; FTC, emtricitabine; HYD, hydroxyurea; IDV, indinavir; IL2, interleukin-2; LPV, lopinavir; MVC, maraviroc; NFV, nelfinavir; NNRTI, non-nucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; NVP, nevirapine; PI, protease inhibitor; RAL, raltegravir; RCT, randomized controlled trial; RIT, ritonavir; RPV, rilpivirine; RTF, ritonavir full dose; SQF, saquinavir fortovase; SQI, saquinavir invirase; TDF, tenofovir disoproxil fumarate.

(DOCX)

Click here for additional data file. (16.6KB, docx)
S2 Table. Patterns of holding regimens by number of previous regimen changes.

Note: ART combinations comprising of less than 5% were grouped as Other. 3TC, lamivudine; ATV/r, atazanavir/ritonavir; AZT, zidovudine; D4T, stavudine; EFV, efavirenz; FTC, emtricitabine; IDV, indinavir; LPV/r, lopinavir/ritonavir; NVP, nevirapine; TDF, tenofovir disoproxil fumarate.

(DOCX)

Click here for additional data file. (13.5KB, docx)

Acknowledgments

Study members of TAHOD and TAHOD-LITE of IeDEA Asia-Pacific:

PS Ly, V Khol, National Center for HIV/AIDS, Dermatology & STDs, Phnom Penh, Cambodia; FJ Zhang, HX Zhao, N Han, Beijing Ditan Hospital, Capital Medical University, Beijing, China; MP Lee, PCK Li, W Lam, YT Chan, Queen Elizabeth Hospital, Hong Kong SAR; N Kumarasamy†, C Ezhilarasi, Chennai Antiviral Research and Treatment Clinical Research Site (CART CRS), VHS-Infectious Diseases Medical Centre, VHS, Chennai, India; S Pujari, K Joshi, S Gaikwad, A Chitalikar, Institute of Infectious Diseases, Pune, India; S Sangle, V Mave, I Marbaniang, S Nimkar, BJ Government Medical College and Sassoon General Hospital, Pune, India; TP Merati, DN Wirawan, F Yuliana, Faculty of Medicine Udayana University & Sanglah Hospital, Bali, Indonesia; E Yunihastuti, A Widhani, S Maria, TH Karjadi, Faculty of Medicine Universitas Indonesia—Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; J Tanuma ‡, S Oka, T Nishijima, National Center for Global Health and Medicine, Tokyo, Japan; JY Choi, Na S, JM Kim, Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea; YM Gani, NB Rudi, Hospital Sungai Buloh, Sungai Buloh, Malaysia; I Azwa, A Kamarulzaman, SF Syed Omar, S Ponnampalavanar, University Malaya Medical Centre, Kuala Lumpur, Malaysia; R Ditangco, MK Pasayan, ML Mationg, Research Institute for Tropical Medicine, Muntinlupa City, Philippines; YJ Chan, WW Ku, PC Wu, E Ke, Taipei Veterans General Hospital, Taipei, Taiwan; OT Ng, PL Lim, LS Lee, D Liang, Tan Tock Seng Hospital, Singapore (note: OT Ng was also supported by the NMRC Clinician Scientist Award (NMRC/CSA-INV/0002/2016), which had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.); A Avihingsanon, S Gatechompol, P Phanuphak, C Phadungphon, HIV-NAT/ Thai Red Cross AIDS Research Centre, Bangkok, Thailand; S Kiertiburanakul, A Phuphuakrat, L Chumla, N Sanmeema, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; R Chaiwarith, T Sirisanthana, J Praparattanapan, K Nuket, Research Institute for Health Sciences, Chiang Mai, Thailand; S Khusuwan, P Kantipong, P Kambua, Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand; KV Nguyen, HV Bui, DTH Nguyen, DT Nguyen, National Hospital for Tropical Diseases, Hanoi, Vietnam; CD Do, AV Ngo, LT Nguyen, Bach Mai Hospital, Hanoi, Vietnam; AH Sohn, JL Ross, B Petersen, TREAT Asia, amfAR—The Foundation for AIDS Research, Bangkok, Thailand; MG Law, A Jiamsakul, R Bijker, D Rupasinghe, The Kirby Institute, UNSW Sydney, NSW, Australia.

† TAHOD Steering Committee Chair; ‡ co-Chair

Data Availability

All relevant data are within the manuscript and its Supporting Information files.

Funding Statement

The TAHOD and TAHOD-LITE studies are initiatives of TREAT Asia, a program of amfAR, The Foundation for AIDS Research, with support from the U.S. National Institutes of Health’s National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Cancer Institute, the National Institute of Mental Health, the National Institute on Drug Abuse, the National Heart, Lung, and Blood Institute, the National Institute on Alcohol Abuse and Alcoholism, the National Institute of Diabetes and Digestive and Kidney Diseases, and the Fogarty International Center (IeDEA; U01AI069907). The Kirby Institute is funded by the Australian Government Department of Health and Ageing. The content of this research is solely the responsibility of the authors and does not necessarily represent the official views of any of the institutions above.

References

  • 1.Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360: 119–129. doi: 10.1016/s0140-6736(02)09411-4 [DOI] [PubMed] [Google Scholar]
  • 2.Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008;359: 339–354. doi: 10.1056/NEJMoa0708975 [DOI] [PubMed] [Google Scholar]
  • 3.Pichenot M, Deuffic-Burban S, Cuzin L, Yazdanpanah Y. Efficacy of new antiretroviral drugs in treatment-experienced HIV-infected patients: a systematic review and meta-analysis of recent randomized controlled trials. HIV Med. 2012;13: 148–155. doi: 10.1111/j.1468-1293.2011.00953.x [DOI] [PubMed] [Google Scholar]
  • 4.Meyers T, Moultrie H, Naidoo K, Cotton M, Eley B, Sherman G. Challenges to pediatric HIV care and treatment in South Africa. J Infect Dis. 2007;196 Suppl 3: S474–481. doi: 10.1086/521116 [DOI] [PubMed] [Google Scholar]
  • 5.Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008;359: 355–365. doi: 10.1056/NEJMoa0708978 [DOI] [PubMed] [Google Scholar]
  • 6.Hatano H, Lampiris H, Fransen S, Gupta S, Huang W, Hoh R, et al. Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy. J Acquir Immune Defic Syndr. 2010;54: 389–393. doi: 10.1097/QAI.0b013e3181c42ea4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Cossarini F, Spagnuolo V, Gianotti N, Carbone A, Lazzarin A, Castagna A. Management of HIV infection after triple class failure. New Microbiol. 2013;36: 23–39 [PubMed] [Google Scholar]
  • 8.The 2018 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-Infected Koreans. Infect Chemother. 2019;51: 77–88. doi: 10.3947/ic.2019.51.1.77 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Ledergerber B, Lundgren JD, Walker AS, Sabin C, Justice A, Reiss P, et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet. 2004;364: 51–62. doi: 10.1016/S0140-6736(04)16589-6 [DOI] [PubMed] [Google Scholar]
  • 10.Raffanti SP, Fusco JS, Sherrill BH, Hansen NI, Justice AC, D’Aquila R, et al. Effect of persistent moderate viremia on disease progression during HIV therapy. J Acquir Immune Defic Syndr. 2004;37: 1147–1154 doi: 10.1097/01.qai.0000136738.24090.d0 [DOI] [PubMed] [Google Scholar]
  • 11.Kantor R, Shafer RW, Follansbee S, Taylor J, Shilane D, Hurley L, et al. Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy. Aids. 2004;18: 1503–1511 doi: 10.1097/01.aids.0000131358.29586.6b [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Goetz MB, Ferguson MR, Han X, McMillan G, St Clair M, Pappa KA, et al. Evolution of HIV resistance mutations in patients maintained on a stable treatment regimen after virologic failure. J Acquir Immune Defic Syndr. 2006;43: 541–549. doi: 10.1097/01.qai.0000245882.28391.0c [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Clotet B, Bellos N, Molina JM, Cooper D, Goffard JC, Lazzarin A, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet. 2007;369: 1169–1178. doi: 10.1016/S0140-6736(07)60497-8 [DOI] [PubMed] [Google Scholar]
  • 14.Teeranaipong P, Sirivichayakul S, Mekprasan S, Ohata PJ, Avihingsanon A, Ruxrungtham K, et al. Role of rilpivirine and etravirine in efavirenz and nevirapine-based regimens failure in a resource-limited country: a cross-sectional study. PloS one. 2016;11: e0154221. doi: 10.1371/journal.pone.0154221 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Zhou J, Kumarasamy N, Ditangco R, Kamarulzaman A, Lee CK, Li PC, et al. The TREAT Asia HIV Observational Database: baseline and retrospective data. J Acquir Immune Defic Syndr. 2005;38: 174–179 doi: 10.1097/01.qai.0000145351.96815.d5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.De La Mata NL, Kumarasamy N, Khol V, Ng OT, Van Nguyen K, Merati TP, et al. Improved survival in HIV treatment programmes in Asia. Antivir Ther. 2016;21: 517–527. doi: 10.3851/IMP3041 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.De La Mata NL, Ly PS, Ng OT, Nguyen KV, Merati TP, Pham TT, et al. Trends in CD4 cell count response to first-line antiretroviral treatment in HIV-positive patients from Asia, 2003–2013: TREAT Asia HIV Observational Database Low Intensity Transfer. Int J STD AIDS. 2017;28: 1282–1291. doi: 10.1177/0956462417699538 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Organization WH. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach: World Health Organization; 2016. [PubMed] [Google Scholar]
  • 19.The World Bank. Countries and Economies 2015. [cited 2015 Feb 02]. Available from: http://data.worldbank.org/country. [Google Scholar]
  • 20.Manosuthi W, Ongwandee S, Bhakeecheep S, Leechawengwongs M, Ruxrungtham K, Phanuphak P, et al. Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014, Thailand. AIDS Res Ther. 2015;12: 12. doi: 10.1186/s12981-015-0053-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.The 2013 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-Infected Koreans. Infect Chemother. 2013;45: 455–461. doi: 10.3947/ic.2013.45.4.455 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Dutta A, Barker C, Kallarakal A. The HIV Treatment Gap: Estimates of the Financial Resources Needed versus Available for Scale-Up of Antiretroviral Therapy in 97 Countries from 2015 to 2020. PLoS Med. 2015;12: e1001907; discussion e1001907. doi: 10.1371/journal.pmed.1001907 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Kumarasamy N, Prabhu S, Chandrasekaran E, Poongulali S, Pradeep A, Chitra D, et al. Safety, Tolerability, and Efficacy of Generic Dolutegravir-containing Antiretroviral Therapy Regimens Among South Indian Human Immunodeficiency Virus-infected Patients. Clin Infect Dis. 2019;68: 1048–1051. doi: 10.1093/cid/ciy763 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Vitoria M, Hill A, Ford N, Doherty M, Clayden P, Venter F, et al. The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues? Aids. 2018;32: 1551–1561. doi: 10.1097/QAD.0000000000001845 [DOI] [PubMed] [Google Scholar]
  • 25.Dorward J, Lessells R, Drain PK, Naidoo K, de Oliveira T, Pillay Y, et al. Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research. Lancet HIV. 2018;5: e400–e404. doi: 10.1016/S2352-3018(18)30093-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Inzaule SC, Hamers RL, Doherty M, Shafer RW, Bertagnolio S, Rinke de Wit TF. Curbing the rise of HIV drug resistance in low-income and middle-income countries: the role of dolutegravir-containing regimens. Lancet Infect Dis. 2019;19: e246–e252. doi: 10.1016/S1473-3099(18)30710-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Jung IY, Rupasinghe D, Woolley I, O’Connor CC, Giles M, Azwa RI, et al. Trends in mortality among ART-treated HIV-infected adults in the Asia-Pacific region between 1999 and 2017: results from the TREAT Asia HIV Observational Database (TAHOD) and Australian HIV Observational Database (AHOD) of IeDEA Asia-Pacific. J Int AIDS Soc. 2019;22: e25219. doi: 10.1002/jia2.25219 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Bell-Gorrod H, Fox MP, Boulle A, Prozesky H, Wood R, Tanser F, et al. The Impact of Delayed Switch to Second-Line Antiretroviral Therapy on Mortality, Depending on Definition of Failure Time and CD4 Count at Failure. Am J Epidemiol. 2020;189: 811–819. doi: 10.1093/aje/kwaa049 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Bell Gorrod H, Court R, Schomaker M, Maartens G, Murphy RA. Increased Mortality With Delayed and Missed Switch to Second-Line Antiretroviral Therapy in South Africa. J Acquir Immune Defic Syndr. 2020;84: 107–113. doi: 10.1097/QAI.0000000000002313 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Smith C, Sabin CA, Lundgren JD, Thiebaut R, Weber R, Law M, et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. Aids. 2010;24: 1537–1548. doi: 10.1097/QAD.0b013e32833a0918 [DOI] [PubMed] [Google Scholar]
  • 31.Cockerham L, Scherzer R, Zolopa A, Rimland D, Lewis CE, Bacchetti P, et al. Association of HIV infection, demographic and cardiovascular risk factors with all-cause mortality in the recent HAART era. J Acquir Immune Defic Syndr. 2010;53: 102–106. doi: 10.1097/QAI.0b013e3181b79d22 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Patten G, Bernheimer J, Fairlie L, Rabie H, Sawry S, Technau K, et al. Lamivudine monotherapy as a holding regimen for HIV-positive children. PLoS One. 2018;13: e0205455. doi: 10.1371/journal.pone.0205455 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Sohn AH, Chokephaibulkit K, Lumbiganon P, Hansudewechakul R, Gani YM, Van Nguyen L, et al. Peritransition Outcomes of Southeast Asian Adolescents and Young Adults With HIV Transferring From Pediatric to Adult Care. Journal of Adolescent Health. 2020;66: 92–99 doi: 10.1016/j.jadohealth.2019.07.025 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Zhou J, Li P, Kumarasamy N, Boyd M, Chen Y, Sirisanthana T, et al. Deferred modification of antiretroviral regimen following documented treatment failure in Asia: results from the TREAT Asia HIV Observational Database (TAHOD). HIV medicine. 2010;11: 31–39 doi: 10.1111/j.1468-1293.2009.00738.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Phanuphak P, Sirivichayakul S, Jiamsakul A, Sungkanuparph S, Kumarasamy N, Lee MP, et al. Transmitted drug resistance and antiretroviral treatment outcomes in non-subtype B HIV1-infected patients in South East Asia. Journal of acquired immune deficiency syndromes (1999). 2014;66: 74. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Jiamsakul A, Sungkanuparph S, Law M, Kantor R, Praparattanapan J, Li PC, et al. HIV multi‐drug resistance at first‐line antiretroviral failure and subsequent virological response in Asia. Journal of the International AIDS Society. 2014;17: 19053 doi: 10.7448/IAS.17.1.19053 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Francisco Javier Fanjul

20 Apr 2021

PONE-D-20-13430

Patterns and prognosis of holding regimens for people living with HIV in Asian countries

PLOS ONE

Dear Dr. Choi,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jun 04 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Francisco Javier Fanjul

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

  1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

  1. Thank you for including your ethics statement:  "Ethics approvals for the study were obtained from local institutional review boards for each participating site, the coordinating center (TREAT Asia/amfAR, Bangkok, Thailand), and the data management and analysis center (Kirby Institute, University of New South Wales, Sydney, Australia). Because of the pure observational nature of the study, written informed consent was waived for both TAHOD and TAHOD-LITE unless required by local institutional review board. All TAHOD and TAHOD-LITE data transfers are anonymized before submission to the Kirby Institute.".  

Please amend your current ethics statement to include the full name of the ethics committee/institutional review board(s) that approved your specific study.

Once you have amended this/these statement(s) in the Methods section of the manuscript, please add the same text to the “Ethics Statement” field of the submission form (via “Edit Submission”).

For additional information about PLOS ONE ethical requirements for human subjects research, please refer to http://journals.plos.org/plosone/s/submission-guidelines#loc-human-subjects-research.

Additional Editor Comments:

Dear authors, Let me first thank you for the opportunity of reviewing your study. I consider that it addresses a very interesting point where no clear evidence has been gathered in the last few years.

However, some points in the paper need to be reconsidered according to reviewers so I hope you can have those suggestions in mind and provide an updated version of the manuscript.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: No

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Kim and colleagues set out to address a very important question in regards to managing patients with limited HIV treatment options in an area of the world highly impacted by the HIV pandemic and with limited access to antiretrovirals compared to higher income world regions.

Their analysis includes many Countries in the region with a variety of incomes, providing breath and generalizability of their findings.

I think their report is interesting and merit publication, however there are some issues that might need to be addressed to improve their message.

Major comments

1. The authors included a cohort where almost half of patients did not have any previous antiretroviral regimen change. Are these patients who are “just” taking a long time to fully respond to treatment as opposed patients truly failing their regimen? From Figure 3 it seems that the proportion of patients with viral load<1000 copies/ml increases over time. Even though it would decrease the overall number of patients in the analysis, would the result show similar findings if only considering patients who had previous ARV changes?

a. More to this point, in the viral load subgroup analysis about 33% of patients had undetectable viral load at week 24. What is the distribution of these patients according to previous ARV changes? Are they all or mostly in the “no previous ARV” group or were they equally distributed?

2. One of the main outcomes that the authors are studying is survival and they specify that “Because all included individuals were alive at 6 months after their second VL test (per the definition of being on a holding regimen), survival time was left truncated at 6 months after the second VL test”. Nonetheless it is not clear what the average follow-up for these cohort was and how many patients were lost to follow-up. It would be important that the authors make it clear, so that the reader know whether these findings have implication in the short, middle or long term.

3. Somewhat related to the previous point, the subgroup analysis for CD4 count and VL only include 24 and 33 patients respectively at week 24. Are the other patients lost to follow-up? If they are not considered as such, how did the authors account for these missing data and what is their definition of lost to follow-up since not having either CD4 or viral load checked at least once within a year, might be considered a fairly standard definition of “lost to follow-up”.

a. In addition, how many patients had CD4 and VL data for week 48? And in terms of VL, how many with VL<200 and <50 at each timepoint?

4. Two major point that would strengthen the message on survival and the consequences of holding regimens would be showing more details regarding the cause of death and development of resistance mutations. I understand that this data might not be available, if that is the case, the authors should make a comment about it in the discussion.

a. In regards to the cause of death, the increased mortality odds that the authors find for higher viral load and lower CD4 count, would imply that the observed deaths are HIV/AIDS related, however with no actual data this remain only speculative.

b. In regards to the development of resistance mutation for patients on holding regimens, this data would be extremely important to help make clinical decision (and possibly/hopefully help develop/revise targeted institutional guidelines) on the importance and optimal timing of modifying failing regimen. As the authors mention in the discussion, the alternative explanation to the persistently elevated viral load in this cohort, would be related to adherence which would obviously need different interventions to be addressed.

Minor comments

Methods

1. The authors mention that their primary outcome for the study is “to identify the patterns of the holding regimen as previously defined” It is however not clear what the authors mean by “patterns” and where these were previously defined

2. Hep C co-infection is defined as positive HCV Antibodies. With no information about HCV RNA or Hep C treatment however, it might be more appropriate to define this variable as “previous Hep C exposure”

Results

1. Related to major point #3, Figures 2 and 3 need to have the #of patients at each timepoint listed underneath

Reviewer #2: Many thanks for the opportunity to review this paper on the use of holding regimens in Asia. While it is an interesting and relevant topic, the authors have not used appropriate methods for all their analyses, some methods are not clear, and they should include calendar year of ART start (or other similar covariate) to account for fewer drug options in the earlier years. A more nuanced discussion of the reasons why some patients are maintained on regimens despite virologic failure is needed. The authors only mention lack of access to other ART options, but in reality, it is possible that patients are not switched due to poor adherence, or the high cost of more robust drugs. This warrants further discussion.

Introduction:

The authors state that holding regimens are used when no fully suppressive cART options are available. Holding regimens are also sometimes used when adherence to ART is judged to be sub-optimal, and clinicians would like to ensure adherence before switching to a new regimen. IT is worth including whether this is the case or not in Asian countries?

Some regimens are also more robust, and patients who have had virological failure may still be able to suppress on these regimens. For example resistance to NNTRIs develops much quicker than resistance to PI-based cART. The reason for maintaining a patient on a regimen following virologic failure may therefore be related to their current regimen, their adherence and the availability of a new regimen. These points should be included.

Methods:

Study population – please clarify what is meant by enrolment – is this ART initiation, from HIV diagnosis, or something different? Please also include details of the years in which patient follow-up began, to give a sense of how long patients that were included in your study were followed. This may also be relevant to understand as the availability of new drugs may have changed and possibly improved in more recent years. Please also clarify database closure for the TAHOD-LITE cohort. It is not clear when the most recent 2017 data transfer provides data until.

The definition of those on holding regimens seems to only include patients who have been maintained on the same cART regimen, and would thus exclude patients on other holding regimens such as lamivudine monotherapy (as mentioned in the intro). Were patients on non-suppressive holding regimens (mono/dual therapy) excluded or was this strategy not used in Asia among adults?

Statistical analyses – how was switch from holding regimen to a new cART regimen dealt with in the survival analysis? Or did all patients remain on their holding regimens until their last recorded visit or death?

Suggest adding calendar year of ART initiation as a covariate – since some drugs such as INSTIs would only have become available in more recent years

One limitation of a linear regression approach to change in CD4 count, is that patients with very low CD4 counts would likely experience only small declines, but possibly larger increases in CD4 compared to those with higher CD4 counts whose CD4 counts could drop by quite a lot, but could not increase by much. The repeated CD4 measures for each patient are therefore not independent. Would recommend using a linear mixed-effects regression model to analyse CD4 changes.

Results:

Descriptive table – include median ART duration at baseline, as well as median follow-up time from enrolment.

Survival Analysis – how many patients were LTFU (the competing risk in the analysis). Suggest adding an outcomes table to indicate how many died, were loss to follow-up, switched to a new cART regimen, virally suppressed on holding regimen or on new regimen.

Discussion:

Could the pattern of holding regimens used by different regions be related to calendar year of ART start? For example do some regions include patients who initiated cART in earlier years than others, when drugs such as INSTIs were not available? This is implied in the limitations section where the authors state that TAHOD patients have been enrolled for longer.

Line 272 – the authors imply that the high mortality rate amongst patients on holding regimens is due to lack of access to further ART options. Patients who have failed treatment are likely to be a more vulnerable group and poor outcomes including mortality could be due to a number of factors including poor adherence.

The discussion could be strengthened by comparing results to studies of patients who have failed to switch regimens, such as

Bell-Gorrod H, et al. The Impact of Delayed Switch to Second-Line Antiretroviral Therapy on Mortality, Depending on Definition of Failure Time and CD4 Count at Failure. Am J Epidemiol. 2020 Aug 1;189(8):811-819. doi: 10.1093/aje/kwaa049. PMID: 32219384; PMCID: PMC7523585.

Bell Gorrod H, Court R, Schomaker M, Maartens G, Murphy RA. Increased Mortality With Delayed and Missed Switch to Second-Line Antiretroviral Therapy in South Africa. J Acquir Immune Defic Syndr. 2020 May 1;84(1):107-113. doi: 10.1097/QAI.0000000000002313. PMID: 32032304; PMCID: PMC7269121.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Mar 30;17(3):e0264157. doi: 10.1371/journal.pone.0264157.r002

Author response to Decision Letter 0

2 Jun 2021

Please amend your current ethics statement to include the full name of the ethics committee/institutional review board(s) that approved your specific study.

Once you have amended this/these statement(s) in the Methods section of the manuscript, please add the same text to the “Ethics Statement” field of the submission form (via “Edit Submission”).

Author’s response

According to your comments, we amended the ethics statement. All participating sites, including our site, have their own ethics approval. However, because it is too long to list the name of all 21 participating sites’ ethics committees, we have revised the ethics statement as follows:

Lines: 106-110

Ethics approvals for the study were obtained from the coordinating center (TREAT Asia ethics/amfAR, Bangkok, Thailand), the data management and analysis center (University of New South Wales Human Research Ethics Committee, Sydney, Australia), and local institutional review boards for each participating site including the institutional review board of Yonsei University Health System Clinical Trial Center.

________________________________________

Review Comments to the Author

Reviewer #1

Major comments

Reviewer’s comment #1

1. The authors included a cohort where almost half of patients did not have any previous antiretroviral regimen change. Are these patients who are “just” taking a long time to fully respond to treatment as opposed patients truly failing their regimen? From Figure 3 it seems that the proportion of patients with viral load<1000 copies/ml increases over time. Even though it would decrease the overall number of patients in the analysis, would the result show similar findings if only considering patients who had previous ARV changes?

Author’s response #1

The patients who did not have any previous ART changes are the ones who are currently on first-line ART. So those patients are currently failing their first-line ART combination.

Although Figure 3 shows increases in VL <1000 copies/mL over time, it is important to note that not all patients had VL at both week 24 and 48. In fact, due to the small sample size, no patient in our study population had both week 24 and 48 VL measurements available. Patients either had VL at week 24 or at week 48. However, there does appear to be an increase in proportion with undetectable VL over time. This could be due to adherence support provided by healthcare providers during the holding regimen period. We were not able to adjust for adherence as TAHOD-LITE does not collect this information. We have included this as a limitation of the study.

As suggested, we have also conducted additional analyses limiting to those who had previous ART regimen changes. For the survival analysis, there were 22 deaths out of 222 patients, with mortality rate of 2.2/100PYS. Only VL was associated with survival (SHR=5.07, 95%CI 2.00-12.87, p=0.001). For the CD4 analysis, there were only 14 patients eligible for the analysis and no factor was associated with CD4 changes in the multivariate analysis. In the VL analysis, there were 6/19 with undetectable VL. Because of the small sample sizes, there was not enough evidence to suggest associations between different variables, however the direction of the associations was similar to our main analyses. We have chosen to maintain patients with no ART changes in our analyses to optimize our sample sizes.

We have also made further clarifications to the manuscript as follows:

Lines: 179-180

“There were 211 (49.7%) patients who had no previous ART regimen changes, i.e. currently failing first-line ART.”

Lines: 258-259

“In Figure 2, there were 28 patients included at 24 weeks and 38 patients at 48 weeks. In Figure 3, of the total 66 patients, 33 patients each were included at 24 and 48 week time points.”

Lines: 328-329

“TAHOD-LITE does not collect ART adherence and therefore, we were not able to assess the impact of adherence counselling on our outcomes”

Reviewer’s comment #1a

a. More to this point, in the viral load subgroup analysis about 33% of patients had undetectable viral load at week 24. What is the distribution of these patients according to previous ARV changes? Are they all or mostly in the “no previous ARV” group or were they equally distributed?

Author’s response #1a

The distribution of undetectable VL according to previous ART regimen changes is roughly equal across groups:

No previous ART regimen changes: 5/14 (36%)

1 previous ART regimen changes: 5/12 (42%)

≥2 previous ART regimen changes: 1/7 (14%)

We have inserted the following in the manuscript:

Lines: 251-253

“The proportion with undetectable VL according to the number of previous ART regimen changes were: no previous ART regimen changes - 5/14 (36%); 1 previous ART changes - 5/12 (42%); and ≥2 previous ART changes - 1/7 (14%).”

Reviewer’s comment #2

2. One of the main outcomes that the authors are studying is survival and they specify that “Because all included individuals were alive at 6 months after their second VL test (per the definition of being on a holding regimen), survival time was left truncated at 6 months after the second VL test”. Nonetheless it is not clear what the average follow-up for these cohort was and how many patients were lost to follow-up. It would be important that the authors make it clear, so that the reader know whether these findings have implication in the short, middle or long term.

Author’s response #2

The median follow-up was 3.1 years (IQR 1.4-6.8). The number of LTFU was 80/425 (18.8%).

We have revised the manuscript as follows:

Lines: 219-221

“Of the 425 patients included in the survival analysis, there were 41 (9.7%) deaths (mortality rate 2.0 per 100 person-years), and 80 (18.8%) were LTFU. The median follow-up time from baseline was 3.1 years (IQR 1.4-6.8).”

Reviewer’s comment #3

3. Somewhat related to the previous point, the subgroup analysis for CD4 count and VL only include 24 and 33 patients respectively at week 24. Are the other patients lost to follow-up? If they are not considered as such, how did the authors account for these missing data and what is their definition of lost to follow-up since not having either CD4 or viral load checked at least once within a year, might be considered a fairly standard definition of “lost to follow-up”.

Author’s response #3

Our cohort’s definition of LTFU is those who have not been seen in the previous 12 months.

For the CD4 and VL analyses, we did not include all patients that were analysed in the survival analysis as our time frame was only restricted to 24 and 48 weeks. According to our inclusion criteria, we only included patients who had CD4 or VL available at 24 weeks or 48 weeks. In the CD4 analysis, 28 patients were included in the 24 week analysis, and 38 patients were included in the 48 week analysis. From the rest of the patients who were not included, only 59 later became LTFU. We did not attempt to include patients without the outcome of interest at 24 and 48 weeks, whether or not they were LTFU, as we did not want to make an assumption of what their CD4 or VL would be. As such, we only restricted our analyses to those who had the outcomes measured at those two time points.

We have made further clarifications in the manuscript as follows:

Lines: 144-145

“PLWH without measurements at these two time points were not included in the analyses.”

Lines: 155-156

“LTFU was defined as those not seen in the previous 12 months.”

Lines: 258-259

“In Figure 2, there were 28 patients included at 24 weeks and 38 patients at 48 weeks. In Figure 3, of the total 66 patients, 33 patients each were included at 24 and 48 week time points.”

Reviewer’s comment #3a

a. In addition, how many patients had CD4 and VL data for week 48? And in terms of VL, how many with VL<200 and <50 at each timepoint?

Author’s response #3a

There were 38 patients who had CD4 at 48 weeks.

For VL, at 24 weeks 7 patients had VL<200 copies/mL, 6 patients had VL<50 copies/mL. At 48 weeks, 11 patients had VL <200 copies/mL, 8 patients had VL <50 copies/mL.

We have included this information in the manuscript as follows:

Lines: 260-263

“At 24 weeks, there were 11 patients with VL <1000 copies/mL, of those 7 patients had VL<200 copies/mL and 6 patients had VL<50 copies/mL. At 48 weeks, there were 15 patients with VL <1000 copies/mL, of those 11 patients had VL <200 copies/mL and 8 patients had VL <50 copies/mL.”

Reviewer’s comment #4 and #4a

4. Two major point that would strengthen the message on survival and the consequences of holding regimens would be showing more details regarding the cause of death and development of resistance mutations. I understand that this data might not be available, if that is the case, the authors should make a comment about it in the discussion.

a. In regards to the cause of death, the increased mortality odds that the authors find for higher viral load and lower CD4 count, would imply that the observed deaths are HIV/AIDS related, however with no actual data this remain only speculative.

Author’s response #4 and #4a

Thank you for your great suggestions. We investigated the cause of death of 41 patients who died in our study population. Out of 41 total deaths, 21 were AIDS-related, 14 were non-AIDS-related, and 6 were deaths by unknown causes. Unlike our results, a prior study on the causes of death in TAHOD patients showed that non-AIDS-related mortality rates were higher than AIDS-related mortality rates in both high/upper-middle income countries and lower-middle income countries [1]. This shows that patients with holding regimens have a higher risk of AIDS-related death than those who do not. The finding was also consistent with the results of this study, where higher viral load and lower CD4 count were identified as risk factors for death.

We have included this information in the manuscript as follows:

Lines: 221-222

Of the 425 patients included in the survival analysis, there were 41 (9.7%) deaths (mortality rate 2.0 per 100 person-years), and 80 (18.8%) were LTFU. The median follow-up time from baseline was 3.1 years (IQR 1.4-6.8). Out of 41 deaths, 21 were AIDS-related, 14 were non-AIDS-related, and 6 were deaths by unknown causes.

Lines: 307-314

Still, there are cases of virologic failure even though a second-line or third-line regimen was already used with no other antiretroviral options available, as in this study. In particular, AIDS-related deaths were more common than non-AIDS-related deaths in this study, which differed from the previous results regarding the cause of death in TAHOD patients, where non-AIDS-related mortality rate was higher than AIDS-related mortality rate [32]. This fact demonstrates the need to extend accessibility to additional antiretroviral options in our region to improve their survival. Regarding factors associated with mortality, it was consistent with what is previously known that old age, high VL, and low CD4 cell counts increased mortality and supported our results that AIDS-related deaths were more common than non-AIDS-related deaths [35,36].

Reviewer’s comment #4b

b. In regards to the development of resistance mutation for patients on holding regimens, this data would be extremely important to help make clinical decision (and possibly/hopefully help develop/revise targeted institutional guidelines) on the importance and optimal timing of modifying failing regimen. As the authors mention in the discussion, the alternative explanation to the persistently elevated viral load in this cohort, would be related to adherence which would obviously need different interventions to be addressed.

Author’s response #4b

We agree with your comment that resistance mutation data is important in determining the timing of failing regimen modifications. Unfortunately, data on resistance mutations in our study subjects were not available. Therefore, there might be concerns that the persistently elevated viral load in this cohort would be related to poor adherence. However, as TAHOD participating sites are generally urban referral centres, and each site recruits patients who are judged to have a reasonably good prospect of long-term follow-up, it is unlikely that holding regimens were used to ensure adherence in this study [2].

Meanwhile, data on resistance mutations in TAHOD patients could be identified by the results of previous studies of TASER-M (TREAT Asia Studies to Evaluate Resistance-Monitoring). According to the research results, transmitted drug resistance was identified in 4.1% (60 out of 1,471 patients); 60% of which had NRTI, 43% NNRTI, and 18% PI-associated mutations [3]. The most common NRTI-associated mutation was M184V, the common NNRTI-associated mutation was K103N or Y181C, and the common PI-associated mutation was M46L [3,4]. The results could be referred to in our study. Nevertheless, the inability to confirm the resistance mutation of this study population was a limitation. Therefore, we have added the following to the limitations.

Lines: 334-340

Fourth, data on resistance mutations in our study population were not available. In previous studies on resistance mutations in TAHOD patients, transmitted drug resistance was identified in 4.1%; 60% of which had NRTI, 43% NNRTI, and 18% PI-associated mutations [39]. The most common NRTI-associated mutation was M184V, the common NNRTI-associated mutation was K103N or Y181C, and the common PI-associated mutation was M46L [39,40]. The results could be referred to in our study.

Minor comments

Methods

Reviewer’s minor comment #1

1. The authors mention that their primary outcome for the study is “to identify the patterns of the holding regimen as previously defined” It is however not clear what the authors mean by “patterns” and where these were previously defined

Author’s response #1

We clarified the sentence as follows:

Lines: 136-137

The primary outcome was identifying which diverse regimens were used as holding regimens in our study population.

Reviewer’s minor comment #2

2. Hep C co-infection is defined as positive HCV Antibodies. With no information about HCV RNA or Hep C treatment however, it might be more appropriate to define this variable as “previous Hep C exposure”

Author’s response #2

We acknowledge that we do not have information on HCV RNA or treatment. However, we have defined Hep C co-infection as those who ever had positive hepatitis C antibody. We do not collect all hepatitis C testing dates, therefore we are not able to determine whether the HCV co-infection was a previous exposure. We have clarified this further in the manuscript as follows:

Lines: 158-159

“hepatitis B/C co-infection defined as ever having positive hepatitis B virus surface antigen or positive hepatitis C virus antibody”

Reviewer’s minor comment results #1

Results

1. Related to major point #3, Figures 2 and 3 need to have the #of patients at each timepoint listed underneath.

Author’s response #1

We have inserted the patient numbers into the graphs. Please see revised Figures 2 and 3.

 

Reviewer #2

Reviewer’s comment #1

Many thanks for the opportunity to review this paper on the use of holding regimens in Asia. While it is an interesting and relevant topic, the authors have not used appropriate methods for all their analyses, some methods are not clear, and they should include calendar year of ART start (or other similar covariate) to account for fewer drug options in the earlier years. A more nuanced discussion of the reasons why some patients are maintained on regimens despite virologic failure is needed. The authors only mention lack of access to other ART options, but in reality, it is possible that patients are not switched due to poor adherence, or the high cost of more robust drugs. This warrants further discussion.

Author’s response #1

We would like to thank the reviewer for the suggestion of including year of ART initiation. We have included this in our analysis.

In terms of the statistical methods, please see below our responses and clarifications under the statistical analysis section. In particular, we have provided further explanation of our chosen methods of statistical analyses and why we believe these are suitable for our datasets and objectives.

We also agree with the comments that there is a need for a more nuanced discussion on why PLWH maintained regimens that did not achieve viral suppression. As described in the Study Population section, we defined holding regimens as those continued for more than 6 months in the same regimen after viral load (VL) ≥1000 copies/mL on two consecutive tests. The basis for this definition was that, in those situations, the regimens would be changed if there were regimens accessible that could achieve viral suppression. Meanwhile, holding regimens are also sometimes used when adherence to ART is judged to be sub-optimal, especially for children who have suspected or proven poor adherence [5]. However, TAHOD is for adult PLWH, and as TAHOD participating sites are generally urban referral centres, and each site recruits patients who are judged to have a reasonably good prospect of long-term follow-up, it is unlikely that holding regimens were used to ensure adherence in this study [2]. How ART adherence affected the results would help strengthen our study, but unfortunately, ART adherence was not collected in TAHOD-LITE. Since this was a limitation of our study, we additionally described it in the Discussion section.

There were also cases where regimen changes could not be made due to the cost of more robust drugs. The reason was of course included as one of the causes of the lack of access to ART described in this study, especially for the resource-limited countries of our cohort.

We have included this information in the manuscript as follows:

Lines: 289-290

For example, in Thailand, one of the UMICs, the 2014 national guidelines recommended EFV, one of the NNRTIs, as the first-line combination, and another NNRTI, NVP was recommended as an alternative drug. PIs were only recommended in second-line combinations and INSTIs in multi-class failure [24]. One reason for this is because many resource-limited countries, such as Thailand, could not financially afford the subsequent regimens [25].

Lines: 329-334

Third, TAHOD-LITE does not collect ART adherence and therefore, we were not able to assess the impact of adherence counselling on our outcomes. Holding regimens are also sometimes used when adherence to ART is judged to be sub-optimal, especially for children who have suspected or proven poor adherence [16,37]. However, TAHOD is for adult PLWH, and as TAHOD participating sites are generally urban referral centres, and each site recruits patients who are judged to have a reasonably good prospect of long-term follow-up, it is unlikely that holding regimens were used to ensure adherence in this study [38].

Introduction:

Reviewer’s comment #2

The authors state that holding regimens are used when no fully suppressive cART options are available. Holding regimens are also sometimes used when adherence to ART is judged to be sub-optimal, and clinicians would like to ensure adherence before switching to a new regimen. IT is worth including whether this is the case or not in Asian countries?

Author’s response #2

As you commented, holding regimens could be used when adherence to ART is judged to be sub-optimal. Holding regimens for this purpose are mainly used in children who have suspected or proven poor adherence [5]. In a study conducted in Southeast Asian countries, holding regimens were used in 3 out of 93 patients who were transferred from a pediatric to an adult clinic [6]. However, TAHOD is for adult PLWH, and as TAHOD participating sites are generally urban referral centres, and each site recruits patients who are judged to have a reasonably good prospect of long-term follow-up, it is unlikely that holding regimens were used to improve adherence in this study [2].

We have added the above information to the Discussion section as follows:

Lines: 329-334

Third, TAHOD-LITE does not collect ART adherence and therefore, we were not able to assess the impact of adherence counselling on our outcomes. Holding regimens are also sometimes used when adherence to ART is judged to be sub-optimal, especially for children who have suspected or proven poor adherence [16,37]. However, TAHOD is for adult PLWH, and as TAHOD participating sites are generally urban referral centres, and each site recruits patients who are judged to have a reasonably good prospect of long-term follow-up, it is unlikely that holding regimens were used to ensure adherence in this study [38].

Reviewer’s comment #3

Some regimens are also more robust, and patients who have had virological failure may still be able to suppress on these regimens. For example resistance to NNTRIs develops much quicker than resistance to PI-based cART. The reason for maintaining a patient on a regimen following virologic failure may therefore be related to their current regimen, their adherence and the availability of a new regimen. These points should be included.

Author’s response #3

We agree with your comments. We have added the following to the Introduction section.

Lines: 82-86

There are no universal criteria for treating PLWH who have experienced multiple treatment failures, because treatment options differ according to the available cART of the countries and likelihood of resistance. For example, patients who develop resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) could achieve viral suppression by changing to a protease inhibitor (PI)-based or an INSTI-based regimen [5,13]. Still, in some cases, since access to the drugs was limited due to problems such as cost and availability, they should maintain their regimens [14].

Methods:

Reviewer’s comment #4

Study population – please clarify what is meant by enrolment – is this ART initiation, from HIV diagnosis, or something different? Please also include details of the years in which patient follow-up began, to give a sense of how long patients that were included in your study were followed. This may also be relevant to understand as the availability of new drugs may have changed and possibly improved in more recent years. Please also clarify database closure for the TAHOD-LITE cohort. It is not clear when the most recent 2017 data transfer provides data until.

Author’s response #4

For TAHOD, enrolment means when patients were recruited and enrolled into the cohort. For TAHOD-LITE, enrolment means the first date the patient was seen at the site. It is not necessarily their date of ART initiation, as the majority of TAHOD patients had already initiated ART prior to enrolment into the cohort. The median year of enrolment into the cohort was 2007 (IQR 2004-2010). The median time of follow-up from baseline time point of the study was 3.1 years (IQR 1.4-6.8). As there was only 1 data transfer for TAHOD-LITE in 2017, the database closure was any time in 2017. The latest visit date for this data transfer was July 2017. We have revised the sentence to make it clearer.

We have inserted the following into the manuscript:

Lines: 117-121

“TAHOD subjects were included if they were enrolled up to the September 2018 data transfer, whilst TAHOD-LITE subjects were included from the 2017 data transfer. For TAHOD, enrolment was the date the patient was recruited into the cohort which can be after ART initiation. For TAHOD-LITE, enrolment was the date the patient was first seen at the site. The latest follow-up date for TAHOD-LITE was July 2017.

Lines: 174-175

“The median year of enrolment into the cohort was 2007 (IQR 2004-2010).”

Lines: 220-221

“The median follow-up time from baseline was 3.1 years (IQR 1.4-6.8).”

Reviewer’s comment #5

The definition of those on holding regimens seems to only include patients who have been maintained on the same cART regimen, and would thus exclude patients on other holding regimens such as lamivudine monotherapy (as mentioned in the intro). Were patients on non-suppressive holding regimens (mono/dual therapy) excluded or was this strategy not used in Asia among adults?

Author’s response #5

We acknowledge that this was unclear. We did include mono/dual therapy in our holding regimen. For our inclusion criteria however, patients had to have at least initiated combination ART (3 or more ARVs) and been on it for least 6 months. The holding regimen itself can be mono/dual therapy.

We have revised the manuscript as follows:

Lines: 121-123

“We defined PLWH meeting all of the following criteria as taking holding regimens: 1) have initiated cART and been on at least 6 months;”

Lines: 125-126

“The holding regimen itself can include mono/dual therapy.”

Reviewer’s comment #6

Statistical analyses – how was switch from holding regimen to a new cART regimen dealt with in the survival analysis? Or did all patients remain on their holding regimens until their last recorded visit or death?

Author’s response #6

We had not intended to assess the effects of ART switches in the survival analysis. This is because the aim was to determine the long term effects of the actual holding regimen that the patient received on their survival, rather than the effects of the current ART regimen. Our analysis was also conducted using intention to treat methods. To analyse ART regimen as a time updated variable, we would have to account for periods of no ART (treatment interruption) which is not within the intention to treat definition. However, we have conducted an additional analysis where we accounted for those who had treatment interruption of more than 14 days and those who had changed any ARV from the holding regimen, and found that there were 271 patients who switched from their holding regimen under this definition. Switches was not associated with survival in the univariate analysis (SHR=0.89, 95%CI 0.48-1.68, p=0.719).

Lines: 156

“Survival time was analysed using intention to treat methods.”

Lines: 230-233

“Additional analyses were conducted where we accounted for changes from holding regimen (any changes to the holding ART or periods of no ART for >14 days). There were 271 patients who had changed out of their holding regimen however it was not associated with survival in the univariate analysis (SHR=0.89, 95%CI 0.48-1.68, p=0.719).”

Reviewer’s comment #7

Suggest adding calendar year of ART initiation as a covariate – since some drugs such as INSTIs would only have become available in more recent years

Author’s response #7

We have included year of ART initiation in the analyses. Please see revised tables. Year of ART initiation was not associated with survival, CD4 changes or undetectable VL.

Reviewer’s comment #8

One limitation of a linear regression approach to change in CD4 count, is that patients with very low CD4 counts would likely experience only small declines, but possibly larger increases in CD4 compared to those with higher CD4 counts whose CD4 counts could drop by quite a lot, but could not increase by much. The repeated CD4 measures for each patient are therefore not independent. Would recommend using a linear mixed-effects regression model to analyse CD4 changes.

Author’s response #8

We would like to clarify the statistical methods used in the CD4 changes analysis. We took the difference between CD4 at 24 weeks and CD4 at baseline for each patient. We then analysed that difference as the outcome in the regression. Each patient therefore only had one single outcome measured. As the outcomes were not repeated measures, but a single outcome, independence was not an issue. Given that there were only 28 patients in the analysis, we believe the simple linear regression used was suitable for our data.

Reviewer’s comment #9

Results:

Descriptive table – include median ART duration at baseline, as well as median follow-up time from enrolment.

Author’s response #9

The median ART duration at baseline was 4.0 years, IQR (1.8-6.9). The median follow-up time from baseline was 3.1 years, IQR (1.4-6.8). We have included this information into the demographics table. Please see revised Table 1.

Reviewer’s comment #10

Survival Analysis – how many patients were LTFU (the competing risk in the analysis). Suggest adding an outcomes table to indicate how many died, were loss to follow-up, switched to a new cART regimen, virally suppressed on holding regimen or on new regimen.

Author’s response #10

There were 80 (18.8%) patients who became LTFU, 41 (9.7%) have died, 271 patients changed from their holding regimen. For the undetectable VL analysis, there were 11/33 patients (33%) who had VL <1000 copies/mL at 24 weeks, and 15/33 (45%) at 48 weeks. As the aim of the study was to determine the effects of the holding regimen on subsequent treatment outcomes, we have not split our undetectable VL outcomes according to treatment switches but have presented the proportions at 24 and 48 weeks. We have decided to add the requested information as text in the relevant results section to make the flow of the paper more coherent. Please see revised manuscript as follows:

Lines: 219-221

“Of the 425 patients included in the survival analysis, there were 41 (9.7%) deaths (mortality rate 2.0 per 100 person-years), and 80 (18.8%) were LTFU. The median follow-up time from baseline was 3.1 years (IQR 1.4-6.8).”

Lines: 232

“There were 271 patients who had changed out of their holding regimen”

Lines: 260-263

“At 24 weeks, there were 11 patients with VL <1000 copies/mL, of those 7 patients had VL<200 copies/mL and 6 patients had VL<50 copies/mL. At 48 weeks, there were 15 patients with Vl <1000 copies/mL, of those 11 patients had VL <200 copies/mL and 8 patients had VL <50 copies/mL.”

Discussion:

Reviewer’s comment #11

Could the pattern of holding regimens used by different regions be related to calendar year of ART start? For example do some regions include patients who initiated cART in earlier years than others, when drugs such as INSTIs were not available? This is implied in the limitations section where the authors state that TAHOD patients have been enrolled for longer.

Author’s response #11

Since the median year of enrolment into the cohort was 2007 (IQR 2004-2010) and as INSTIs have not been widely available across all TAHOD sites, there were not many patients who were on INSTI in the holding regimen in our study group even if we were looking at holding regimens in more recent years. As shown in S1 Table, the cases in which INSTIs were used were limited in the subjects of this study (19 cases out of 425 cases). In this study, we could not identify the changes in patterns of holding regimen after INSTIs became widely available, and this should be investigated through follow-up studies. We have added the following to the Discussion section regarding these limitations and perspectives.

Lines: 324-328

Second, TAHOD has patients who have been enrolled for a long time, so the data may reflect holding regimen in previous years. Since the median year of enrolment into the cohort was 2007 (IQR 2004-2010) and as INSTIs have not been widely available across all TAHOD sites, we could not identify the changes in patterns of holding regimen after INSTIs became widely available. Follow-up studies are warranted in this regard.

Reviewer’s comment #12

Line 272 – the authors imply that the high mortality rate amongst patients on holding regimens is due to lack of access to further ART options. Patients who have failed treatment are likely to be a more vulnerable group and poor outcomes including mortality could be due to a number of factors including poor adherence.

The discussion could be strengthened by comparing results to studies of patients who have failed to switch regimens, such as

Bell-Gorrod H, et al. The Impact of Delayed Switch to Second-Line Antiretroviral Therapy on Mortality, Depending on Definition of Failure Time and CD4 Count at Failure. Am J Epidemiol. 2020 Aug 1;189(8):811-819. doi: 10.1093/aje/kwaa049. PMID: 32219384; PMCID: PMC7523585.

Bell Gorrod H, Court R, Schomaker M, Maartens G, Murphy RA. Increased Mortality With Delayed and Missed Switch to Second-Line Antiretroviral Therapy in South Africa. J Acquir Immune Defic Syndr. 2020 May 1;84(1):107-113. doi: 10.1097/QAI.0000000000002313. PMID: 32032304; PMCID: PMC7269121.

Author’s response #12

Thank you for introducing those valuable studies. We reviewed the papers you introduced and compared them with our findings. It was consistent with our findings that in the case of virologic failure, a remaining regimen resulted in a poor prognosis. Meanwhile, our study analyzed not only cases of virologic failure with the first-line regimen, but also cases that experienced virologic failure while using the second-line or third-line regimen. This is because our study population was defined as cases where no other antiretroviral option was currently available, regardless of the history of previous ART changes. Therefore, there were some differences in the populations of our study and the studies you introduced, and this is the basis for claiming the need for further ART options in our study.

We have cited the papers you introduced and strengthened the discussion of our manuscript as follows:

Lines: 301-307

The mortality rate of PLWH with holding regimens was more than twice that of other PLWH in our cohort reported in previous study [32]. This was consistent with the results of previous studies that the prognosis of a remaining regimen or a delay in switching regimens was poor in patients with virologic failure [33,34]. The reasons for no switch or a delayed switch could be multifactorial, such as prolonged time-period before confirmation of virologic failure or doubts about adequate patient adherence [33,34]. Still, there are cases of virologic failure even though a second-line or third-line regimen is already used with no more other antiretroviral options available, as in this study.

References

1. Jung IY, Rupasinghe D, Woolley I, O'Connor CC, Giles M, Azwa RI, et al. Trends in mortality among ART-treated HIV-infected adults in the Asia-Pacific region between 1999 and 2017: results from the TREAT Asia HIV Observational Database (TAHOD) and Australian HIV Observational Database (AHOD) of IeDEA Asia-Pacific. J Int AIDS Soc. 2019;22: e25219. doi:10.1002/jia2.25219 PMID:30615271

2. Zhou J, Li P, Kumarasamy N, Boyd M, Chen Y, Sirisanthana T, et al. Deferred modification of antiretroviral regimen following documented treatment failure in Asia: results from the TREAT Asia HIV Observational Database (TAHOD). HIV medicine. 2010;11: 31-39

3. Phanuphak P, Sirivichayakul S, Jiamsakul A, Sungkanuparph S, Kumarasamy N, Lee MP, et al. Transmitted drug resistance and antiretroviral treatment outcomes in non-subtype B HIV1-infected patients in South East Asia. Journal of acquired immune deficiency syndromes (1999). 2014;66: 74

4. Jiamsakul A, Sungkanuparph S, Law M, Kantor R, Praparattanapan J, Li PC, et al. HIV multi‐drug resistance at first‐line antiretroviral failure and subsequent virological response in Asia. Journal of the International AIDS Society. 2014;17: 19053

5. Patten G, Bernheimer J, Fairlie L, Rabie H, Sawry S, Technau K, et al. Lamivudine monotherapy as a holding regimen for HIV-positive children. PloS one. 2018;13: e0205455

6. Sohn AH, Chokephaibulkit K, Lumbiganon P, Hansudewechakul R, Gani YM, Van Nguyen L, et al. Peritransition Outcomes of Southeast Asian Adolescents and Young Adults With HIV Transferring From Pediatric to Adult Care. Journal of Adolescent Health. 2020;66: 92-99

Attachment

Submitted filename: Response_to_Reviewers_20210601.docx

Click here for additional data file. (52KB, docx)

Decision Letter 1

Carlo Torti

6 Dec 2021

PONE-D-20-13430R1

Patterns and prognosis of holding regimens for people living with HIV in Asian countries

PLOS ONE

Dear Dr. Choi,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Still there are comments from reviewer #2 which need to be addressed (modify the analysis or provide a well justified rebuttal).

Please submit your revised manuscript by Jan 20 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Carlo Torti

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Additional Editor Comments:

Still there are comments from reviewer #2 which need to be addressed (modify the analysis or provide a well justified rebuttal).

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Thank you for addressing my comments and adding additional information to your work. I believe this will be an informative paper for the field.

Reviewer #2: Many thanks to the authors for addressing my original comments. I have two additional comments:

The authors should consider amending the first paragraph of the discussion for better clarity on the holding regimens that were used. The authors note in the introduction that there are several types of holding regimens including lamivudine monotherapy, recycling previously used drugs or adding new ARVs to an existing regimen. It is not clear from the results or the discussion what was the case in this study, although it seems as if patients were simply maintained on their failing regimen.

The authors have now added to the definition of a patient taking a holding regimen to include those on mono/dual therapy. Usually patients on these regimens do not have their viral load taken because it is not a virally suppressive regimen. Your definition of a holding regimen includes have 2 consecutive VL>1000 within 6 months on the same regimen. I recommend removing the mono/dual therapy from the definition of holding regimen, unless there were in fact patients who were placed on this regimen.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Mar 30;17(3):e0264157. doi: 10.1371/journal.pone.0264157.r004

Author response to Decision Letter 1

17 Dec 2021

Reviewer #2: Many thanks to the authors for addressing my original comments. I have two additional comments:

Reviewer’s comment #1

The authors should consider amending the first paragraph of the discussion for better clarity on the holding regimens that were used. The authors note in the introduction that there are several types of holding regimens including lamivudine monotherapy, recycling previously used drugs or adding new ARVs to an existing regimen. It is not clear from the results or the discussion what was the case in this study, although it seems as if patients were simply maintained on their failing regimen.

Author’s response #1

Thank you for your comments. We have defined holding regimen in the Methods section as follows:

“We defined PLWH meeting all of the following criteria as taking holding regimens: 1) have initiated cART and been on it forat least 6 months; 2) had virologic failure defined as viral load (VL) ≥1000 copies/mL on two consecutive tests performed within 6 months while on the same regimen; and 3) then remained on the same regimen for at least 6 months after the second VL test. The holding regimen itself can include mono/dual therapy. These definitions applied regardless of the number of drugs that make up the regimen or the category of regimen the subject was on (e.g., 1st, 2nd, or 3rd regimen). Subjects who switched after the first VL test and subjects who switched before 24 weeks after the second VL test were excluded because they did not meet the definition of holding regimen (Fig 1).”

The reviewer is correct in that our definition criteria does not specify that a patient has to be on certain ART combinations to be considered a holding regimen. The patient only has to remain on their failing regimen. We have revised the manuscript for clarification as follows:

[Introduction]

When no fully suppressive cART options are available, providers may choose to maintain patients on “holding regimens” in anticipation of future treatments [7]. The use of holding regimens could have effects on the future immunologic and clinical outcomes of the PLWH.

[Discussion]

HIV management has been shifting from prevention of opportunistic infections to managing HIV as a chronic disease with a focus on addressing non-communicable diseases and improving quality of life. However, this paradigm shift is only possible when PLWH are on virally suppressive cART regimens, which may not be achievable when there is drug resistance or limited access to the antiretroviral drug options. This has led to the reliance on holding regimens in anticipation of future treatments. We found that 3TC + AZT + EFV was the most commonly used holding regimen in our Asia regional cohort, followed by 3TC + AZT + NVP.

Reviewer’s comment #2

The authors have now added to the definition of a patient taking a holding regimen to include those on mono/dual therapy. Usually patients on these regimens do not have their viral load taken because it is not a virally suppressive regimen. Your definition of a holding regimen includes have 2 consecutive VL>1000 within 6 months on the same regimen. I recommend removing the mono/dual therapy from the definition of holding regimen, unless there were in fact patients who were placed on this regimen.

Author’s response #2

Thank you for your comments. As in answer to the previous comment, mono/dual therapy could also be included in the holding regimen only when it meets our study's definition. As shown in the S1 Table, there were several cases where dual therapy was used in our study population. These cases met the definition of a holding regimen which includes 2 consecutive VL>1000 within 6 months on the same regimen. As these cases met the definition of a holding regimen, we included them in our analysis. We revised the sentences to better express that cases that meet the definition of the holding regimen are included regardless of the number of drugs.

[Materials and methods]

Study population

We defined PLWH meeting all of the following criteria as taking holding regimens: 1) have initiated cART and been on it for at least 6 months; 2) had virologic failure defined as viral load (VL) ≥1000 copies/mL on two consecutive tests performed within 6 months while on the same regimen [22]; and 3) then remained on the same regimen for at least 6 months after the second VL test. The holding regimen itself can include mono/dual therapy. These definitions applied regardless of the number of drugs that make up the regimen or the category of regimen the subject was on (e.g., 1st, 2nd, or 3rd regimen).

Attachment

Submitted filename: Second_Response_to_reviewers_Final.docx

Click here for additional data file. (16.8KB, docx)

Decision Letter 2

Carlo Torti

7 Feb 2022

Patterns and prognosis of holding regimens for people living with HIV in Asian countries

PONE-D-20-13430R2

Dear Dr. Choi,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Carlo Torti

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Carlo Torti

22 Mar 2022

PONE-D-20-13430R2

Patterns and prognosis of holding regimens for people living with HIV in Asian countries

Dear Dr. Choi:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Carlo Torti

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. Detailed patterns of holding regimens.

    3TC, lamivudine; ABC, abacavir; ATV, atazanavir; AZT, zidovudine; COB, cobicistat; D4T, stavudine; DDC, zalcitabine; DDI, didanosine; DRV, darunavir; EFV, efavirenz; ETV, etravirine; EVG, elvitegravir; FAP, fosamprenavir; FTC, emtricitabine; HYD, hydroxyurea; IDV, indinavir; IL2, interleukin-2; LPV, lopinavir; MVC, maraviroc; NFV, nelfinavir; NNRTI, non-nucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; NVP, nevirapine; PI, protease inhibitor; RAL, raltegravir; RCT, randomized controlled trial; RIT, ritonavir; RPV, rilpivirine; RTF, ritonavir full dose; SQF, saquinavir fortovase; SQI, saquinavir invirase; TDF, tenofovir disoproxil fumarate.

    (DOCX)

    Click here for additional data file. (16.6KB, docx)
    S2 Table. Patterns of holding regimens by number of previous regimen changes.

    Note: ART combinations comprising of less than 5% were grouped as Other. 3TC, lamivudine; ATV/r, atazanavir/ritonavir; AZT, zidovudine; D4T, stavudine; EFV, efavirenz; FTC, emtricitabine; IDV, indinavir; LPV/r, lopinavir/ritonavir; NVP, nevirapine; TDF, tenofovir disoproxil fumarate.

    (DOCX)

    Click here for additional data file. (13.5KB, docx)
    Attachment

    Submitted filename: Response_to_Reviewers_20210601.docx

    Click here for additional data file. (52KB, docx)
    Attachment

    Submitted filename: Second_Response_to_reviewers_Final.docx

    Click here for additional data file. (16.8KB, docx)

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting Information files.

    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES